TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05518292

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rhomboid intercostal block
Description: Ultrasound guided RIB will apply with 10-12 MHz linear ultrasound transducer, in plane technique. Patients will placed in the sitting position. 22G spinal needle needle will be inserted to plane between the rhomboid muscle and intercostal muscles over the T5-6 ribs 2 cm to 3 cm medially from the medial border of the scapula. 20 ml of bupivacaine 0.25% will inject into the fascial plane.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serratus anterior plane block
Description: Patients will placed in the lateral position with the diseased side up. A 10-12 MHz linear ultrasound transducer is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The fifth rib is identified in the mid-axillary line. The following muscles are identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). As an extra-reference point, the thoracodorsal artery is used to aid the identification of the plane superficial to the serratus muscle. The needle (22G spinal needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance, 20 ml of bupivacaine 0.25% will inject.
Study: NCT04121481

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement
Description: Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement
Description: Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Broad Spectrum Safety
Description: Benefits in Sports Nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broad Spectrum Safety
Description: Benefits in Sports Nutrition
Study: NCT04860960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl-beta-cyclodextrin
Description: Dose is 2000 mg/kg body weight provided every 2 weeks intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl-beta-cyclodextrin
Description: Dose is 2000 mg/kg body weight provided every 2 weeks intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5N saline provided every 2 weeks intravenously
Study: NCT05414097

Intervention type: OTHER
Intervention: Semi-structured focus group discussions - Women
Description: Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.

Intervention type: OTHER
Intervention: semi-structured focus groups discussions - Men
Description: Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening.

Intervention type: OTHER
Intervention: In-depth key stakeholders interviews
Description: In-depth interviews to contextualise findings from women and men focus group discussions.

Intervention type: OTHER
Intervention: Discrete Choice Experiment - Women
Description: Discrete Choice Experiment to determine preferences to different cancer screening models.

Intervention type: OTHER
Intervention: Development and User Pre-testing Workshops
Description: Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 \&2.
Study: NCT05431530

Intervention type: PROCEDURE
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery including resection of tumors involving rectosigmoid colon.
Study: NCT05034861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cCTG
Description: Self-applied home computerized CTG device used twice weekly instead of standard Doppler assessment once weekly.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Doppler
Description: Standard Doppler assessment provided once weekly in case of late FGR with positive end diastolic flow in the umbilical artery.
Study: NCT05943288

Intervention type: DEVICE
Intervention: OIP-1
Description: Olympus Endoscopy Computer-Aided Detection (CADe) system
Study: NCT06648265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (Topical)
Description: Add 250 mg of TXA per liter of Klein\&#39;s Tumescent solution for arm liposculpture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tumescent solution with dilute lidocaine and epinephrine
Description: Arm infiltration with traditional Klein\&#39;s tumescent solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumescent solution with dilute lidocaine and epinephrine
Description: Arm infiltration with traditional Klein\&#39;s tumescent solution
Study: NCT04693936

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical Combination Plan
Description: Multivitamin (My Total Health) 1 tablet per day Vitamin C (My Immuno) 1 scoop per day Calcium-Magnesium combination (My Calmag) 1 scoop per day Omega 3-6-9 My Omega Krill. 1 capsule per day Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day Probiotics 40 billion 1 capsule per day~Nutraceuticals will be received daily along with the patient's customary psoriasis/Hashimoto's disease treatment.
Study: NCT05763758

Intervention type: OTHER
Intervention: No intervention
Description: No intervention involved in this study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention involved in this study
Study: NCT04923295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Effect of Dapagliflozin on ultrafiltration and PET results among peritoneal dialysis patients
Study: NCT06205732

Intervention type: OTHER
Intervention: Immunotherapy, targeted therapy.
Description: Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
Study: NCT05125523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus for Injection (Albumin Bound)
Description: Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)
Study: NCT06647654

Intervention type: BIOLOGICAL
Intervention: ABRYSVO
Description: Test Negative Design: This is a non-interventional retrospective study; therefore, ABSYRVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.~Ecologic Before-and-After Design: This is an ecologic before-and-after study using aggregated data; as such, the 'exposure' of interest is time before ABRYSVO program implementation (i.e., five historical pre-ABRYSVO RSV seasons) and time after ABRYSVO implementation (i.e., post-ABRYSVO RSV seasons: 2024-2026).

Intervention type: BIOLOGICAL
Intervention: ABRYSVO
Description: Test Negative Design: This is a non-interventional retrospective study; therefore, ABSYRVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.~Ecologic Before-and-After Design: This is an ecologic before-and-after study using aggregated data; as such, the 'exposure' of interest is time before ABRYSVO program implementation (i.e., five historical pre-ABRYSVO RSV seasons) and time after ABRYSVO implementation (i.e., post-ABRYSVO RSV seasons: 2024-2026).

Intervention type: BIOLOGICAL
Intervention: ABRYSVO
Description: Test Negative Design: This is a non-interventional retrospective study; therefore, ABSYRVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.~Ecologic Before-and-After Design: This is an ecologic before-and-after study using aggregated data; as such, the 'exposure' of interest is time before ABRYSVO program implementation (i.e., five historical pre-ABRYSVO RSV seasons) and time after ABRYSVO implementation (i.e., post-ABRYSVO RSV seasons: 2024-2026).
Study: NCT05867719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic breathing conditions
Description: Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic breathing conditions
Description: Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic breathing conditions
Description: Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.
Study: NCT05596513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor learning and occupational therapy
Description: 1. Constraint-induced movement therapy (CIMT)~2. Hand-arm bimanual intensive training (HABIT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Learning Approaches From Working on a Vertical Surface
Description: 1. Ball on wall, kneel to stand~2. Kneel walk cross over~3. Vertical playground puzzles and games~4. Color on big boxes~5. Fridge magnets~6. Erasing a whiteboard or chalkboard~7. Tactile feedback from textured walls
Study: NCT05012475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Virtual Reality Gaming
Description: Investigators customize each gaming session based on the motivators and interests of each participant. The intervention facilitates independent hand separations (minimizing stereotypies) and encourages independent arm/hand movement that serves to activate or control the computer-generated activities.
Study: NCT05137379

Intervention type: BEHAVIORAL
Intervention: A joint functional score based on the affected joint
Description: A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )
Study: NCT06388811

Intervention type: OTHER
Intervention: Early Osteoarthritis Questionnaire
Description: Self administered questionnaire

Intervention type: OTHER
Intervention: Early Osteoarthritis Questionnaire
Description: Self administered questionnaire
Study: NCT06151990

Intervention type: OTHER
Intervention: lipid profile
Description: Measurements for CHOL,TG,LDL-C and HDL-C obtained following an overnight fasting

Intervention type: OTHER
Intervention: lipid profile
Description: Measurements for CHOL,TG,LDL-C and HDL-C obtained following an overnight fasting

Intervention type: OTHER
Intervention: lipid profile
Description: Measurements for CHOL,TG,LDL-C and HDL-C obtained following an overnight fasting
Study: NCT04879459

Intervention type: OTHER
Intervention: Practical sessions to learn CUS exclusively on volunteers presenting a healthy gallbladder
Description: The study days are 1 day apart for CG and IG but follow the exact same organization. Studytake place on day 0-10-30 (+/-2days). Practical sessions to learn CUS are organized either on volunteers presenting a healthy gallbladder or a pathological gallbladder (sludge, gallstones) (CG), either exclusively on volunteers presenting a healthy gallbladder (IG).
Study: NCT06120673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive an intravenous infusion of 1,000mg Obinutuzumab at Weeks 0, 2, 24 and 26.~Prior to the administration of obinutuzumab, the participant will receive pre-medications consisting of all three:~* IV methylprednisolone 80 mg,~* Paracetamol 1,000 mg orally,~* Either cetirizine 10 mg orally or diphenhydramine 50 mg orally. These pre-medications must be completed between 30 to 60 minutes prior to the obinutuzumab infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone and cyclophosphamide
Description: Participants will receive a combination of oral prednisolone and cyclophosphamide with 2 options (Option A and B).~Option A: Cyclical prednisolone and cyclophosphamide with IV methylprednisolone~* IV methylprednisolone 500-1000 mg will be given on days 1, 2 and 3 at the start of months 1, 3, and 5.~* Oral prednisolone will be given at 0.5 mg/kg/day (max 50 mg/day) in months 1, 3, and 5.~* Oral cyclophosphamide will be given in months 2, 4 and 6, adjusted by age and weight~Option B: Concurrent prednisolone and cyclophosphamide without IV methylprednisolone~* Oral prednisolone will be given to meet a cumulative dose equivalent to 0.5 mg/kg/day for 90 days (max 50 mg/day).~* Oral cyclophosphamide will be given for 90 days, adjusted by age and weight
Study: NCT04703296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBAT course
Description: The MBAT will involve:~(i) 4 weekly 1.5-hour course sessions. The sessions will provide guided exercises, didactic information, and discussions to promote greater mindfulness.~(ii) Daily mindfulness practice that will be facilitated by the Measuring Mindfulness App (MMA) and/or instructor-delivered mindfulness practices. The daily mindfulness practice will require about 15 minutes to complete.
Study: NCT06456099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Description: Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus tendons on the greater trochanter of the hip at baseline, Prior to the beginning of exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Our exercise protocol is based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of eight weeks (see appendix 6, Træningsvejledning). Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled. Compliance to exercises are measured using a training diary that the participants must fill out during the study period (see appendix 7, Træningsdagbog).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient information leaflet
Description: In order to support self-management and modification of tendon load, participants will receive a handout at baseline that contains information about GTPS and advice on load management (see appendix 8, Folder - Smerter på ydersiden af hoften). The participants will be encouraged to read the leaflet regularly and follow the advice.
Study: NCT04811053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR021618
Description: Treatment group A: HR021618 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group B: Saline injection
Study: NCT04518098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength and balance exercise
Description: The exercise program consists of muscle strengthening and balance training exercises that progress in difficulty. After completion of the baseline assessment and randomization, IG participants will receive orientation and learn the exercise routines (in the Cancer Rehabilitation Clinic within the Faculty of Rehabilitation Medicine at the University of Alberta). The duration of training is 3 months (40-50 minutes per scheduled session, three times a week) at home, with a minimum of one live group session supervised by the CEP, a minimum of one independent home session supported by the Active Living module of the HEAL-ME application; (the third session can be a live session or independent session at the participant's discretion).
Study: NCT05966935

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fenugreek Cumin Powder
Description: Fenugreek and Cumin seeds will be procured from the market. They will be cleaned of debris, winnowed, and grinded to fine powder passed through a mesh size of 30 for metal cleaning. 5g of fenugreek powder and 5g of cumin powder will be packed in packets. Participants in the intervention group will be instructed to consume the powder before breakfast and dinner with a glass of water.
Study: NCT05745428

Intervention type: OTHER
Intervention: molecular and cellular analyses
Description: sample blood

Intervention type: OTHER
Intervention: molecular and cellular analyses
Description: sample blood
Study: NCT04588233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Each subject will receive 3mg of melatonin 1 hour prior to bedtime for 12 consecutive nights

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will receive a placebo 1 hour prior to bedtime for 12 consecutive nights
Study: NCT06051487

Intervention type: OTHER
Group type: OTHER
Intervention: titanium dioxide nanoparticles in test group
Description: Titanium dioxide nanoparticles added to acrylic baseplate in test group

Intervention type: OTHER
Group type: OTHER
Intervention: titanium dioxide nanoparticles in test group
Description: Titanium dioxide nanoparticles added to acrylic baseplate in test group
Study: NCT05647551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX®/VISTABEL®
Description: Facial Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLBELLA® with Lidocaine
Description: Facial Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLIFT® with Lidocaine
Description: Facial Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLUMA® with Lidocaine
Description: Facial Injection
Study: NCT04954586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Informed Movement
Description: Participants will attend a twice weekly exercise program.
Study: NCT06178952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation Verum
Description: Participants are slated to undergo a total of five TPS sessions over a 10-day interval. Each stimulation session will endure approximately 30 minutes and will be administered once daily.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial pulse stimulation Sham
Description: Placebo treatment will be performed using the same medical device, handpiece and treatment paradigm as in the verum treatment with one difference: the standoff device at the end of the handpiece. This device is designed to replicate the appearance, feel, and sound of the verum system, while omitting the transmission of any pulses.
Study: NCT04287725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exercise + photobiomodulation therapy
Description: Treatment sessions will be provided twice a week for 6 weeks (totaling 12 sessions) with participants receiving either placebo or active PBMT + exercise protocol.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: exercise + photobiomodulation therapy
Description: Treatment sessions will be provided twice a week for 6 weeks (totaling 12 sessions) with participants receiving either placebo or active PBMT + exercise protocol.
Study: NCT04724629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: 80 mg of IL-17 inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 1.5 million IU (low-dose) of IL-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5 mg of indirect IL-6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: Active comparator (Corticoids and antiretrovirals)
Study: NCT06071143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KDSTEM Inj.
Description: 1. Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10\^8 cells/10mL/2 syringes)~2. High dose: The following study drugs are pre-mixed with 70mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10\^8 cells/30mL/6 syringes)
Study: NCT06488495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Program
Description: The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.
Study: NCT06419686

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Intravenous saline during experimental days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP
Description: Intravenous GIP administration during experimental days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alanine
Description: Intravenous alanine administration during experimental days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP + alanine
Description: Intravenous administration of GIP and alanine during experimental days.
Study: NCT01000220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05528718

Intervention type: DRUG
Intervention: Nitrous oxide gas for inhalation
Description: This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.

Intervention type: DRUG
Intervention: Midazolam injection
Description: This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.